{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005116","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.027687+00:00","generated_at":"2026-05-17T19:47:20.376028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent","bullets":["Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.","Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.","Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.","ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.","R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005116","json":"https://secwatch.observer/filing/0001171843-25-005116.json","markdown":"https://secwatch.observer/filing/0001171843-25-005116.md","text":"https://secwatch.observer/filing/0001171843-25-005116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/0001171843-25-005116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/f8k_080625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:47:20.376028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}